Skip to content
  1. Home
  2. life sciences
  3. focus areas
  4. glp 1

Driving Therapeutic Development

Glucagon-like-peptide-1 (GLP-1) agonist clinico-genomic registry

Unleash the world’s most dynamic precision clinical research network and accelerate therapeutic development by accessing Helix's rapidly growing clinico-genomic registry of GLP-1 agonist treated patients. By integrating longitudinal clinical data with deep genomic insights via exome sequencing from a diverse patient population, our dataset is designed to provide researchers with critical insights to better understand response to current GLP-1s and develop next-generation precision therapies.

Connect with Us
Abstarct shapes with blue and other light colors for the background

The largest GLP-1 clinico-genomic registry in the world

Built as part of the Helix Research Network (HRN), the cohort consists of whole Exome+® sequencing profiles for over 18,000 GLP-1 agonist treated patients combined with longitudinal and regularly refreshed EHR data including demographics, clinical diagnoses (T2D, CVD, obesity, kidney diseases, etc), lab results, & procedures, as well as linked medical and pharmacy claims data.

Cohort Highlights

3X growth

Cohort Size: 3X growth in cohort size over the last 12 months

>10 GLP-1 agents included

GLP-1 agents included: >10 comprising of Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exanatide and others



~14yrs Average patient EHR history look-back

average patient EHR history: ~14yrs lookback including diagnoses, lab results, prescriptions and much more

Longitudinal Clinical Insights

By identifying and analyzing variants in GLP1R associated with diabetes, Helix has divided the cohort into patients diagnosed with T2D vs. those without a clinical diagnosis.

Longitudinal clinical insights with multiple measurements for a range of key metabolic lab measurements including HbA1c, Triglycerides, LDLs and more in a majority of patients.

Patient population ranges from healthy weight to Body Mass Index (BMI) readings greater than 40 to enable the analysis and impact of GLP-1 receptor agonists for obesity.

Research Insights

Despite semaglutide’s proven efficacy in diabetes and obesity treatment, there is significant heterogeneity in weight loss experienced by patients and genetic factors remain unclear. Helix researcher, Dr. Matt Levy, recently presented groundbreaking analysis using Helix data to identify key metabolic and genetic factors associated with weight loss in semaglutide, evaluated the impact of established BMI polygenic risk scores (PGS), and more.

Watch the latest webinar >

Helix Advantages

Longitudinal Clinical Insights

De-identified, OMOP-standardized EHR integrations, including full clinical data & lab results, across North America. Regular data refreshes enable life sciences to follow the patient journey beyond an initial encounter.

Whole Exome+ Sequencing

Deep genomic insights using Helix’s comprehensive and proprietary exome platform covering hundreds of genes implicated in cardiovascular, metabolic, and other related diseases.

Patient Consent

Full consent for recontact for enrollment in research studies, clinical trials, and surveys.

World class Analytical Capabilities

Dedicated in-house translational research team to support life sciences’ analytical and research needs.

Additional Resources

Press Releases

Helix Launches World's Largest Clinico-Genomic Cohort of GLP-1 Agonist Treated Patients

Read More

Research

White Paper: Semaglutide and Weight Management

Read More

Webinars

Metabolic risk factors and BMI-associated variants influencing weight loss with Semaglutide

Read More

Connect with us!